MacroGenics Announces Proposed Public Offering of Common Stock
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/16/2026
- S&P 500, Nasdaq set for lower open as chip weakness weighs
- TSMC Q2 profit jumps 77% to record, far surpasses expectations
- Oil rises over 1% as Iran threat puts Red Sea route at risk
- Citi sees Google, Meta and Amazon capex spending at over $800 billion in 2027
- UnitedHealth shares surge on strong earnings beat and guidance
Macrogenics (MGNX) Prices 4.5M Common Stock Offering at $21.25/Share
March 28, 2018 7:31 AM EDTMacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced the pricing of an underwritten public offering of 4,500,000 shares of its common stock at a public offering price of $21.25 per share, before underwriting discounts and commissions. In addition, MacroGenics has granted the underwriters a 30-day option to purchase up to an additional 675,000 shares of common stock at the public offering price, less underwriting discounts and commissions.
Leerink Partners, Deutsche Bank Securities and Evercore Group L.L.C. are... More
